What is the price target for TVTX stock?
21 analysts have analysed TVTX and the average price target is 43.47 USD. This implies a price increase of 8.4% is expected in the next year compared to the current price of 40.1.
TRAVERE THERAPEUTICS INC (TVTX) Forecast, Price Target & Analyst Ratings
NASDAQ:TVTX • US89422G1076
Current stock price
40.1 USD
-0.79 (-1.93%)
At close:
40.1 USD
0 (0%)
After Hours:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for TRAVERE THERAPEUTICS INC (TVTX).
Forecast Snapshot
Next Earnings Forecast
Earnings Estimate- Release Date
- Apr 30, 2026
- Period
- Q1 / 2026
- EPS Estimate
- -$0.22
- Revenue Estimate
- 139M
Price Target Details & History
Consensus Price Target and Range
Mean target
$43.47
Upside
+ 8.40%
From current price of $40.10 to mean target of $43.47, Based on 21 analyst forecasts
Low
$31.31
Median
$42.84
High
$51.45
Price Target Revisions
1 Month
-0.23%
3 Months
0.95%
Price Target Summary
21 Wall Street analysts provided a forecast for the next 12 months for TVTX. The average price target is 43.47 USD. This implies a price increase of 8.4% is expected in the next year compared to the current price of 40.1.
The average price target has been revised upward by 0.95% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
84.76%
TVTX was analyzed by 21 analysts. The buy percentage consensus is at 85. So analysts seem to be very confident about TVTX.
In the previous month the buy percentage consensus was at a similar level.
TVTX was analyzed by 21 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-04-24 | Guggenheim | Maintains | Buy -> Buy |
| 2026-04-14 | Guggenheim | Maintains | Buy -> Buy |
| 2026-04-14 | Wedbush | Maintains | Outperform -> Outperform |
| 2026-04-14 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2026-04-14 | Citigroup | Maintains | Buy -> Buy |
| 2026-04-14 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2026-03-25 | JP Morgan | Maintains | Overweight -> Overweight |
| 2026-02-06 | Piper Sandler | Maintains | Neutral -> Neutral |
| 2025-11-28 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-11-04 | Piper Sandler | Maintains | Neutral -> Neutral |
| 2025-10-31 | TD Cowen | Maintains | Buy -> Buy |
| 2025-09-19 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-09-12 | Stifel | Maintains | Hold -> Hold |
| 2025-09-11 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-09-10 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-09-03 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-08-28 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-08-07 | ScotiaBank | Maintains | Sector Outperform -> Sector Outperform |
| 2025-08-07 | Wedbush | Maintains | Outperform -> Outperform |
| 2025-06-11 | Citigroup | Maintains | Buy -> Buy |
| 2025-05-16 | Wedbush | Reiterate | Outperform -> Outperform |
| 2025-05-02 | Stifel | Maintains | Hold -> Hold |
| 2025-05-02 | Wedbush | Reiterate | Outperform -> Outperform |
| 2025-04-23 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2025-04-14 | Guggenheim | Reiterate | Buy -> Buy |
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- Apr 30, 2026
- Period
- Q1 / 2026
- EPS Estimate
- -$0.22
- Revenue Estimate
- 139M
- Revenue Q2Q
- 70.07%
- EPS Q2Q
- 54.18%
- Number of Analysts
- 15
Next Earnings Revisions
Revenue (1 Month)
-0.37%
Revenue (3 Months)
2.07%
EPS (1 Month)
-6.14%
EPS (3 Months)
-57.20%
Next Earnings Summary
TVTX is expected to report earnings on 4/30/2026. The consensus EPS estimate for the next earnings is -0.22 USD and the consensus revenue estimate is 139.00M USD.
The next earnings revenue estimate has been revised upward by 2.07% in the past 3 months.
Full Analyst Estimates 2026 - 2033
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 145.238M -31.49% | 233.175M 60.55% | 490.728M 110.45% | 710.38M 44.76% | 962.67M 35.51% | 1.111B 15.41% | 1.395B 25.56% | 1.613B 15.63% | 1.922B 19.16% | 2.158B 12.28% | 2.115B -1.99% | |
| EBITDA YoY % growth | -338.214M -44.90% | -212.629M 37.13% | -2.081M 99.02% | 147.68M 7,196.59% | 388.34M 162.96% | 612.32M 57.68% | 786.74M 28.49% | 1.158B 47.19% | 1.134B -2.07% | 1.301B 14.73% | N/A | |
| EBIT YoY % growth | -376.744M -41.37% | -256.184M 32.00% | -62.824M 75.48% | 52.22M 183.12% | 174.81M 234.76% | 365.96M 109.35% | 512.76M 40.11% | 670.02M 30.67% | 797.66M 19.05% | 917.16M 14.98% | 1.048B 14.27% | |
| Operating Margin | -259.40% | -109.87% | -12.80% | 7.35% | 18.16% | 32.94% | 36.76% | 41.54% | 41.50% | 42.50% | 49.55% | |
| EPS YoY % growth | -4.60 -5.26% | -4.10 10.87% | -0.30 92.68% | 0.17 157.46% | 1.97 1,042.01% | 2.45 24.52% | 7.75 216.12% | 9.69 25.01% | 12.26 26.56% | 13.74 12.04% | 14.10 2.66% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.22 54.18% | -0.09 36.53% | 0.05 -83.00% | 0.54 1,697.75% | 0.49 327.37% | 0.65 834.70% | 0.86 1,699.87% | 0.91 68.32% |
| Revenue Q2Q % growth | 139M 70.07% | 162.29M 41.80% | 186.99M 13.42% | 223.19M 72.10% | 213.9M 53.88% | 240.28M 48.06% | 257.97M 37.96% | 272.15M 21.94% |
| EBITDA Q2Q % growth | 13.326M 144.61% | 60.186M 324.80% | 87.433M 29.46% | 85.847M 203.19% | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -11.997M 71.89% | 12.307M 197.29% | 24.324M -2.43% | 63.347M 295.35% | N/A | N/A | N/A | N/A |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
116.67%
EPS Next 5 Year
102.79%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
29.38%
Revenue Next 5 Year
25.75%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
159.80%
EBIT Next 5 Year
99.22%
TRAVERE THERAPEUTICS INC / TVTX Forecast FAQ
What is the next earnings date for TVTX stock?
TRAVERE THERAPEUTICS INC (TVTX) will report earnings on 2026-04-30.
Can you provide the consensus estimates for TRAVERE THERAPEUTICS INC next earnings?
The consensus EPS estimate for the next earnings of TRAVERE THERAPEUTICS INC (TVTX) is -0.22 USD and the consensus revenue estimate is 139.00M USD.
How do analysts rate TRAVERE THERAPEUTICS INC (TVTX)?
The consensus rating for TRAVERE THERAPEUTICS INC (TVTX) is 84.7619 / 100 . This indicates that analysts generally have a positive outlook on the stock.